CL2008000249A1 - Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus - Google Patents
Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirusInfo
- Publication number
- CL2008000249A1 CL2008000249A1 CL200800249A CL2008000249A CL2008000249A1 CL 2008000249 A1 CL2008000249 A1 CL 2008000249A1 CL 200800249 A CL200800249 A CL 200800249A CL 2008000249 A CL2008000249 A CL 2008000249A CL 2008000249 A1 CL2008000249 A1 CL 2008000249A1
- Authority
- CL
- Chile
- Prior art keywords
- papilomavirus
- papilom
- viric
- codifies
- understands
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07360004 | 2007-01-30 | ||
EP07360018 | 2007-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008000249A1 true CL2008000249A1 (es) | 2008-05-30 |
Family
ID=39399907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200800249A CL2008000249A1 (es) | 2007-01-30 | 2008-01-29 | Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus |
Country Status (20)
Country | Link |
---|---|
US (1) | US8420103B2 (es) |
EP (2) | EP2390340A3 (es) |
JP (1) | JP5474567B2 (es) |
KR (1) | KR101636575B1 (es) |
CN (1) | CN101617052A (es) |
AR (1) | AR065076A1 (es) |
AT (1) | ATE518958T1 (es) |
AU (1) | AU2008209759B2 (es) |
BR (1) | BRPI0806350A2 (es) |
CA (1) | CA2675355C (es) |
CL (1) | CL2008000249A1 (es) |
DK (1) | DK2118292T3 (es) |
IL (2) | IL199939A (es) |
MX (1) | MX2009008118A (es) |
PE (1) | PE20081723A1 (es) |
PL (1) | PL2118292T3 (es) |
RU (2) | RU2482189C2 (es) |
TW (1) | TW200840869A (es) |
WO (1) | WO2008092854A2 (es) |
ZA (1) | ZA200904932B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR065074A1 (es) * | 2007-05-15 | 2009-05-13 | Transgene Sa | Peptidos de senalizacion |
MX2009012272A (es) * | 2007-05-15 | 2009-12-01 | Transgene Sa | Vectores para la expresion de genes multiples. |
WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
WO2015149051A1 (en) * | 2014-03-28 | 2015-10-01 | The Johns Hopkins University | Treatment regimen using cancer vaccines and local adjuvants and their use |
CA2965562C (en) * | 2014-11-04 | 2023-11-21 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv16 vaccines |
CN109862939A (zh) * | 2016-06-03 | 2019-06-07 | 埃特彼塞斯公司 | 用于治疗人***瘤病毒(hpv)相关疾病的组合物和方法 |
EP3518966A1 (en) * | 2016-09-29 | 2019-08-07 | GlaxoSmithKline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
EP3641803A2 (en) | 2017-06-21 | 2020-04-29 | Transgene | Personalized vaccine |
EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
US11012555B2 (en) * | 2017-11-20 | 2021-05-18 | International Business Machines Corporation | Non-verbal sensitive data authentication |
WO2019151760A1 (ko) * | 2018-02-02 | 2019-08-08 | 주식회사 에스엘백시젠 | 신규 다가 hpv 백신 조성물 |
MX2020009262A (es) | 2018-03-07 | 2021-01-08 | Transgene | Vectores de parapoxvirus. |
CN116200416B (zh) * | 2023-02-15 | 2024-03-12 | 北京康乐卫士生物技术股份有限公司 | 一种基于Tac启动子的质粒表达载体构建及其用途 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
DE3642912A1 (de) | 1986-12-16 | 1988-06-30 | Leybold Ag | Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer |
FR2632863B2 (fr) | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
US5100587A (en) | 1989-11-13 | 1992-03-31 | The United States Of America As Represented By The Department Of Energy | Solid-state radioluminescent zeolite-containing composition and light sources |
US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
US5179993A (en) | 1991-03-26 | 1993-01-19 | Hughes Aircraft Company | Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid |
DE4123760C2 (de) | 1991-07-18 | 2000-01-20 | Dade Behring Marburg Gmbh | Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2 |
US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
US5674703A (en) * | 1992-12-02 | 1997-10-07 | Woo; Savio L. C. | Episomal vector systems and related methods |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
CN1152935A (zh) * | 1994-05-16 | 1997-06-25 | 麦克公司 | ***状瘤病毒疫苗 |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
FR2749323B1 (fr) | 1996-06-04 | 1998-07-10 | Pasteur Merieux Serums Vacc | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
US6485958B2 (en) | 1996-07-01 | 2002-11-26 | Gencell Sa | Method for producing recombinant adenovirus |
EP0968284B1 (en) | 1996-11-20 | 2006-12-13 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
AU5370598A (en) | 1996-12-13 | 1998-07-03 | Schering Corporation | Methods for purifying viruses |
EP0988053A1 (en) | 1997-06-11 | 2000-03-29 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
WO1999014377A2 (en) | 1997-09-16 | 1999-03-25 | Innogenetics N.V. | Detection and identification of human papillomavirus by pcr and type-specific reverse hybridization |
WO2000046355A2 (en) | 1999-02-04 | 2000-08-10 | Geron Corporation | Telomerase reverse transcriptase transcriptional regulatory sequences |
FR2774699B1 (fr) * | 1997-11-17 | 2003-10-03 | Rhone Poulenc Rorer Sa | Methode de reduction des evenements de recombinaison homologue |
FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
JP3864610B2 (ja) | 1998-05-21 | 2007-01-10 | 旭硝子株式会社 | 水分散型撥水撥油剤組成物およびその製造方法 |
US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
US20020037274A1 (en) | 1998-10-26 | 2002-03-28 | Angelica Williams | Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
US6582693B2 (en) * | 1998-11-30 | 2003-06-24 | Lemery, S.A. De C.V. | Recombinant MVA virus expressing the E2 gene of Bovine papillomavirus and its use in the therapy of tumors generated by papillomaviruses |
FR2787465A1 (fr) | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
AU779267B2 (en) | 1998-12-31 | 2005-01-13 | Centelion S.A.S. | Method for separating viral particles |
EP1155120B1 (fr) | 1999-02-22 | 2006-07-05 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
ATE284898T1 (de) | 1999-08-25 | 2005-01-15 | Merck & Co Inc | Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind |
ES2288488T3 (es) | 1999-11-15 | 2008-01-16 | Onyx Pharmaceuticals, Inc. | Adenovirus oncoliticos. |
CA2341356C (en) | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
US20020029498A1 (en) | 2000-07-03 | 2002-03-14 | Howard Harrison | Rapid cool iron and related iron improvements |
WO2002008435A1 (en) | 2000-07-21 | 2002-01-31 | Glaxo Group Limited | Codon-optimized papilloma virus sequences |
JP4080423B2 (ja) | 2001-05-30 | 2008-04-23 | トランジェーヌ、ソシエテ、アノニム | アデノウイルスタンパク質ix、ならびにキャプシドアセンブリー、転写活性および核再組織化に関与するそのドメイン |
US20050118139A1 (en) | 2001-08-23 | 2005-06-02 | Lingyi Huang | Vaccine using papilloma virus e proteins delivered by viral vector |
EA007811B1 (ru) * | 2002-05-16 | 2007-02-27 | Бавариан Нордик А/С | Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva) |
GB0222953D0 (en) * | 2002-10-03 | 2002-11-13 | Glaxo Group Ltd | Novel Compounds |
AU2003290460A1 (en) * | 2003-12-24 | 2005-07-14 | Leiden University Medical Center | Synthetic protein as tumor-specific vaccine |
CA2552508A1 (en) | 2003-12-31 | 2005-09-29 | Pharmexa Inc. | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
-
2008
- 2008-01-29 EP EP11175811A patent/EP2390340A3/en not_active Withdrawn
- 2008-01-29 DK DK08708349.9T patent/DK2118292T3/da active
- 2008-01-29 WO PCT/EP2008/051032 patent/WO2008092854A2/en active Application Filing
- 2008-01-29 AT AT08708349T patent/ATE518958T1/de not_active IP Right Cessation
- 2008-01-29 KR KR1020097016704A patent/KR101636575B1/ko active IP Right Grant
- 2008-01-29 AU AU2008209759A patent/AU2008209759B2/en not_active Ceased
- 2008-01-29 EP EP08708349A patent/EP2118292B1/en not_active Not-in-force
- 2008-01-29 JP JP2009547667A patent/JP5474567B2/ja not_active Expired - Fee Related
- 2008-01-29 AR ARP080100357A patent/AR065076A1/es not_active Application Discontinuation
- 2008-01-29 CN CN200880003650A patent/CN101617052A/zh active Pending
- 2008-01-29 RU RU2009130791/10A patent/RU2482189C2/ru not_active IP Right Cessation
- 2008-01-29 BR BRPI0806350-8A patent/BRPI0806350A2/pt not_active Application Discontinuation
- 2008-01-29 CA CA2675355A patent/CA2675355C/en not_active Expired - Fee Related
- 2008-01-29 PL PL08708349T patent/PL2118292T3/pl unknown
- 2008-01-29 PE PE2008000212A patent/PE20081723A1/es not_active Application Discontinuation
- 2008-01-29 MX MX2009008118A patent/MX2009008118A/es active IP Right Grant
- 2008-01-29 CL CL200800249A patent/CL2008000249A1/es unknown
- 2008-01-29 US US12/449,197 patent/US8420103B2/en not_active Expired - Fee Related
- 2008-01-29 TW TW097103230A patent/TW200840869A/zh unknown
-
2009
- 2009-01-01 ZA ZA200904932A patent/ZA200904932B/xx unknown
- 2009-07-19 IL IL199939A patent/IL199939A/en active IP Right Grant
-
2011
- 2011-10-06 IL IL215599A patent/IL215599A/en not_active IP Right Cessation
-
2013
- 2013-01-17 RU RU2013102035/10A patent/RU2013102035A/ru unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010516287A (ja) | 2010-05-20 |
PE20081723A1 (es) | 2008-12-14 |
WO2008092854A3 (en) | 2008-10-30 |
JP5474567B2 (ja) | 2014-04-16 |
US20100143408A1 (en) | 2010-06-10 |
IL215599A0 (en) | 2011-11-30 |
EP2118292B1 (en) | 2011-08-03 |
IL199939A0 (en) | 2010-04-15 |
RU2013102035A (ru) | 2014-07-27 |
EP2390340A2 (en) | 2011-11-30 |
WO2008092854A2 (en) | 2008-08-07 |
ZA200904932B (en) | 2010-04-28 |
KR20090129399A (ko) | 2009-12-16 |
EP2390340A3 (en) | 2012-02-22 |
IL215599A (en) | 2014-11-30 |
CN101617052A (zh) | 2009-12-30 |
MX2009008118A (es) | 2009-10-13 |
US8420103B2 (en) | 2013-04-16 |
CA2675355A1 (en) | 2008-08-07 |
RU2482189C2 (ru) | 2013-05-20 |
AU2008209759A1 (en) | 2008-08-07 |
AR065076A1 (es) | 2009-05-13 |
TW200840869A (en) | 2008-10-16 |
PL2118292T3 (pl) | 2011-12-30 |
KR101636575B1 (ko) | 2016-07-05 |
CA2675355C (en) | 2015-04-28 |
ATE518958T1 (de) | 2011-08-15 |
DK2118292T3 (da) | 2011-10-24 |
EP2118292A2 (en) | 2009-11-18 |
BRPI0806350A2 (pt) | 2011-09-06 |
AU2008209759B2 (en) | 2013-03-21 |
IL199939A (en) | 2013-02-28 |
RU2009130791A (ru) | 2011-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008000249A1 (es) | Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus | |
MX2012001592A (es) | Composicion para el tratamiento de la infección del virus de la hepatitis b. | |
BR112012010676A2 (pt) | partícula de alta eficiência que compreende um agente de benefício. | |
CL2015003615A1 (es) | Nucleósidos sustituidos, nucleótidos y análogos de los mismos. | |
DK3192874T3 (da) | Virusoprensning | |
EP3057592A4 (en) | Hepatitis b viral assembly effectors | |
BRPI0922312A2 (pt) | método, e, meio legível por computador | |
DK2242752T3 (da) | Imidazolyl-biphenylimidazoler som hepatitis C-virus-inhibitorer | |
BR112013003706A2 (pt) | processo para copolimerizar olefinas polimerizáveis, complexo de ligante-metal, catalisador e ligante | |
BRPI0818194A2 (pt) | meio legível por computador | |
BR112013003243A2 (pt) | monômeros de escrita de (metil) acrilato difuncionais | |
HK1222180A1 (zh) | 用於生物樣品中的具有提高的性能的 測定 | |
BRPI1011516A2 (pt) | aglomerado de pelo menos uma partícula p, processo para a produção de aglomerados, e, uso dos aglomerados. | |
ECSP15011603A (es) | Subunidades de vacunas de inmersión para peces | |
CL2011002478A1 (es) | Metodo y un sistema para controlar el uso de un dispositivo electronico al menos por un usuario que comprende verificar si al menos una condicion restrictiva relacionada al uso de dicho dispositivo ha sido satisfecha. | |
HK1118563A1 (en) | Influenza viruses able to infect canids, uses thereof | |
BR112015008391A2 (pt) | processo para o pós-tratamento de um material zeolítico, material zeolítico e uso do mesmo. | |
JP2013140343A5 (es) | ||
BRPI0821034A2 (pt) | Vírus influenza modificado | |
BR112013017489A2 (pt) | materiais e métodos para genotipagem e quantificação de um papiloma vírus humano de alto risco | |
EA201491490A1 (ru) | Самовыравнивающийся бетон | |
BRPI0922574A2 (pt) | processo para purificar metil metacrilato, metil metacrilato, e, polímero. | |
EP3091010A4 (en) | 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene hepatitis c virus inhibitor and application thereof | |
DK2910576T3 (da) | Carrageenan, der er modificeret ved hjælp af ionbytningsproces | |
FI20090030A0 (fi) | Onkolyyttiset virukset |